L-Dopa, an intermediate in the biosynthesis of catecholamines, is now widely used in the treatment of parkinsonism. A number of clinical observations suggested that L-dopa may induce changes in its own metabolism during the course of therapy. In the present study, it was found that when L-dopa was administered to rats, the activity of liver aromatic L-amino-acid decarboxylase, the enzyme which catalyzes the conversion of dopa to dopamine, was reduced by as much as 50%. There were no corresponding changes in enzyme activity in heart, adrenals, kidneys, and brain. Decarboxylase activity in the liver continued to decrease for at least 5 days after the last dose of L-dopa. The reduction of enzyme activity in the liver occurred when L-dopa was administered either subcutaneously or orally at doses comparable to those used clinically. In vitro and in vivo experiments indicated that this action of L-dopa is not due to some effect on the cofactor, pyridoxal phosphate. Immunological evidence was obtained that enzyme protein is reduced in the same proportion as enzyme activity. By a reduction of decarboxylase activity in liver without any affect on the enzyme in brain, more L-dopa should be made available to the brain for decarboxylation to dopamine. These findings may explain the clinical observations that the therapeutic efficacy of the drug increases with continued administration.
It is now apparent that the activities and amounts of the enzymes that synthesize norepinephrine can be modified by various experimental procedures (1) (2) (3) (4) (5) (6) (7) (8) . The use of high doses of one of the intermediates, 3,4-dihydroxy-L-phenylalanine (L-dopa), in the treatment of parkinsonism prompted us to investigate its actions in vivo on the three enzymes involved in norepinephrine biosynthesis. In earlier reports, it was shown that tissue levels of tyrosine hydroxylase (9, 10) and dopamine-p-hydroxylase (EC 1.14.2.1; manuscript in preparation) are reduced in animals treated with L-dopa. In the tissues investigated previously, the levels of aromatic Iamino-acid decarboxylase* were not modified to any great extent (9) . However, several observations with parkinsonian patients on -dopa therapy suggested that this agent may, with time, induce alterations in its own metabolism, possibly at the decarboxylation step. It is known that the therapeutic efficacy of L-dopa increases with continued therapy (12, 13) . Another finding is that administration of pyridoxine, the vitamin analog of pyridoxal phosphate, antagonizes the theraAbbreviation: Dopa, 3,4-dihydroxyphenylalanine. * This enzyme was originally named dopa decarboxylase (EC 4.1.1.26). Later work showed it to be capable of decarboxylating several aromatic L-amino acids. See ref. (11) and references therein.
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peutic effectiveness of L-dopa (14, 15) . These observations led us to investigate dopa decarboxylase activity in additional tissues and revealed that administration of L-dopa markedly lowers the enzyme activity in the liver without affecting this enzyme in the brain.
MATERIALS AND METHODS
Female Sprague Dawley rats (190-210 g) obtained from Carworth Farms, New City, N.Y. were used. [Carboxyl-14C]-D3,4-dihydroxyphenylalanine (5 Ci/mol) was obtained from New England Nuclear Corp. L-3,4-Dihydroxyphenylalanine (L-dopa) and pyridoxal phosphate were kindly supplied by Hoffmann-La Roche, Inc., Nutley, N.J. L-Dopa was administered as a fine suspension in 0.9% NaCl.
Rats were routinely fasted 16 hr before they were killed and their tissues were immediately frozen until assayed. Tissues were homogenized in 5 volumes of 5 mM sodium phosphate (pH 7.2) except for the adrenal glands. Pairs of adrenals were homogenized in 2 ml of buffer. Homogenates were centrifuged at 30,000 X g for 10 min and the supernatants were assayed for aromatic L-amino-acid decarboxylase activity as described (11) , with idopa as substrate. Activity is expressed as nanomoles decarboxylated per wet weight of tissue.
The preparation of goat antiserum to aromatic L-aminoacid decarboxylase of hog kidney has been described (11, 16) . The antiserum was monospecific by double-diffusion assay and immunoelectrophoresis, and was shown to crossreact with the decarboxylase from several other mammals, including the rat (16) . The method used to follow the antigenantibody reaction was similar to that of Feigelson and Greengard (17) .
Statistical analysis of the data was made by Student's t-test.
RESULTS
When high doses of -dopa were administered to rats over a period of several days, a large reduction in the activity of aromatic -amino-acid decarboxylase of the liver was observed (Table 1) . By contrast, the activities in heart, kidney, adrenals, and brain were unaltered by idopa administration (Table 2 ).
Since the amount of -dopa that lowered the activity of liver decarboxylase (Table 1) was high in comparison to the dose given to parkinsonian patients, an experiment was done to determine how little of the drug would be effective. As shown in Fig. 1 , the lowest dose of i.-dopa (100 mg/kg per day) Rats were given L-dopa (1000 mg/kg per day, subcutaneously) or 0.9% NaCl for 3 consecutive days. After 2 days without drug, this regimen was repeated for 2 additional days; the rats were killed 1 day after the last dose. Liver supernatants were assayed for decarboxylase activity.
* Numbers in parentheses refer to the number of animals used. t Significanl;ly different from control (P < 0.001).
resulted in a small, but significant, reduction in liver decarboxylase after 4 days of treatment. This dose is comparable to that used clinically. As the dose was increased, decarboxylase activity fell progressively.
To determine how long liver-decarboxylase activity remained depressed after discontinuation of L-dopa, the following experiment was performed. Animals were given L-dopa or saline for four consecutive days and then killed 1, 2, 3, or 5 days later. Surprisingly, after L-dopa administration was discontinued, liver decarboxylase activity continued to fall and was at its lowest 5 days after the last dose (Fig. 2 ). This effect of L-dopa is, therefore, time-dependent. In fact, even large doses of L-dopa (1000 mg/kg per day) had no effect when administered for 2 days or less.
Since the administration of pyridoxine reverses the therapeutic effects of L-dopa in parkinsonian patients (14, 15) , it was important to see whether the effects of the amino acid were related to the cofactor of decarboxylase, pyridoxal phosphate. As shown in Fig. 3 , decarboxylase activities in liver supernatants of animals treated with L-dopa and of control animals were stimulated to the same extent by exogenous pyridoxal phosphate. The decarboxylase activity of the group treated with L-dopa remained half that of the control group, even when assayed with concentrations of exogenous pyridoxal phosphate up to 70 MM, which is essentially satu- rating (18, 19) . The concomitant administration of pyridoxine * HCl (5 mg/kg per day, interperitoneally) with L-dopa (500 mg/kg per day) for four consecutive days did Rats were given 0.9% NaCl or -dopa orally with a stomach tube. The daily dosage listed in the table was given in divided doses three times a day. This regimen was maintained for 7 consecutive days; the rats were killed 1 day after the last dose. Liver supernatants were assayed for decarboxylase activity. Six rats were used in each group.
* Significantly different from control (P < 0.001).
not modify the i-dopa-mediated decrease in liver-decarboxylase activity. In all of the above studies, L-dopa was administered subcutaneously in order to obtain a slow, continuous release of the compound between doses. Since i-dopa is given orally when used in treating parkinsonism, it was necessary to determine whether similar effects could be obtained in rats on an oral regimen. The results of such studies are shown in Table 3 . It can be seen that orally administered idopa, at a dose of 100 mg/kg per day, which is comparable to that administered to many parkinsonian patients, effectively lowered liver decarboxylase activity within 7 days. It is of interest that there was no further reduction in enzymatic activity at higher doses. Conceivably, even lower doses may be effective.
The question remained as to whether L-dopa treatment lowered decarboxylase activity by modifying the enzyme or Livers from control rats and rats treated with -dopa (1000 mg/kg, subcutaneously, for 4 days, killed on the fifth day) were homogenized in three volumes of 5 mM sodium phosphate buffer (pH 7.2). The homogenates were centrifuged at 20,000 X g for 15 min. The supernatants were assayed and found to contain 263 and 134 enzyme units/mil, respectively. The control supernatant was diluted with an equal volume of buffer and aliquots of the diluted control and L-dopa-treated supernatants were incubated with 5 utl of antiserum for 1 hr at room temperature. The incubation mixtures contained 0.9% NaCl; 5 mM sodium phosphate buffer (pH 7.2); 5 ul of antiserum; 0.05, 0.1 0.2, or 0.3 ml of enzyme; and sufficient bovine-serum albumin to maintain a roughly constant total protein concentration, all in a total volume of 1 ml. Control mixtures contained a /1 of serum from a goat immunized against another enzyme. After incubation, the mixtures were centrifuged at 100,000 X g for 60 min and 0.4-ml aliquots of the supernatants were assayed in duplicate. Decarboxylase activity remaining after treatment with antiserum has been corrected for the small amount of activity that was lost in the presence of the control (goat) serum.
* 1 unit of enzyme activity is defined as that amount of enzyme that yields 1 nmol of C02/min under the conditions of the standard assay.
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liver enzyme does not appear to differ from that in the other tissues by any criteria, including immunologic crossreactivity (16) . Conceivably, decarboxylase in tissues such as stomach and small intestine (20, 21) might also be reduced by L-dopa administration. Just how idopa brings about a decrease in the amount of an enzyme involved in its own metabolism is not clear. Generally, administration of a substrate induces its metabolic enzymes. This effect has been found in microorganisms and animals (22, 23) . To our knowledge, the reverse effect has only been reported for one other compound. Morphine, when given chronically, causes a reduction in the activities of N-demethylase and glucuronyl transferase, two enzymes involved in its metabolism (24, 25) . It is possible that the effective agent is a metabolite of iLdopa, rather than the amino acid itself. It should be kept in mind that administration of idopa can diminish the activity of tyrosine hydroxylase in several peripheral, sympathetically innervated tissues (9, 10) as a result of an overproduction of catecholamines (manuscript in preparation). Similar effects have been shown to occur in the adrenal gland with respect to dopamine-f3-hydroxylase (manuscript in preparation). In contrast, decarboxylase activity remained unchanged in these same tissues, while the only demonstrable change occurred in the liver.
It seems clear that L-dopa does not exert its effect on liver decarboxylase through an interaction with the cofactor pyridoxal phosphate, and that the fall in enzyme activity is most likely the result of a diminished amount of enzyme protein. The finding that pyridoxine can abolish the beneficial effects of iLdopa therapy cannot be explained by the present studies. It should be noted that the dose of pyridoxine used in these studies is capable of reversing the therapeutic efficacy of idopa in parkinsonian patients (14, 15) .
Decarboxylation is a major route of -dopa metabolism. Since the liver is one of the richest sources of dopa-decarboxylase activity, it probably accounts for much of the peripheral metabolism of Lidopa given to patients with parkinsonism. The progressive decrease in the liver enzyme, without a concomitant decrease in the brain enzyme, should make more -dopa available to the brain and thereby yield more dopamine and norepinephrine in the central nervous system. These results are consistent with observations of enhanced therapeutic efficacy and the reduction in the necessary maintenance dose after prolonged treatment with L-dopa (12, 13) .
It is of interest that one of the aims of clinical investigators has been to develop an inhibitor of peripheral L-dopa decarboxylation to make more L-dopa available to the brain.
In fact, two such selective inhibitors have been used experimentally to lower the dose of Lidopa needed for therapy of parkinsonism (26, 27 
